.jpg?format=webp&width=780)
A study evaluated gut bacterial signatures in 62 lung cancer patients treated with anti-PD1 immunotherapy to identify biomarkers that predict treatment efficacy. The study found that patients with longer progression-free survival (PFS) had a different beta-diversity profile compared to those with short PFS and chemotherapy-treated patients had a different profile compared to chemotherapy-naive patients. Patients with short PFS had an increased abundance of Firmicutes and Actinobacteria phyla, and an elevated F/B ratio. Multivariate analysis identified specific bacteria associated with long and short PFS. Using a machine learning approach, taxonomic profiles were found to predict PFS better, while metabolic pathways predicted PD-L1 expression.
Like
Save
Share